J. Van Laethem

发表

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

A. Drouillard, F. Puleo, J. Bachet, 2016, British Journal of Cancer.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

David Goldstein, Florence Huguet, Franck Bonnetain, 2016, JAMA.

A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results.

P. Rougier, J. Infante, J. Stephenson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer

J. Iovanna, N. Dusetti, J. Emile, 2021, Translational oncology.

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Sabine Tejpar, Bruno Landi, Simona Rossi, 2014, Clinical Cancer Research.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Marc Peeters, Bart Neyns, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

D. Sargent, P. Laurent-Puig, R. Goldberg, 2017, JAMA oncology.

Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018.

E. Van Cutsem, M. Ducreux, W. Schmiegel, 2018, European journal of cancer.

Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?

M. Peeters, T. Price, J. Van Laethem, 2009, The oncologist.

Argon Plasma Coagulation in the Treatment of Barrett’s High-Grade Dysplasia and In Situ Adenocarcinoma

J. Devière, J. Van Laethem, M. Cremer, 2001, Endoscopy.

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Machiels, J. Tabernero, R. Kurzrock, 2014, Clinical Cancer Research.

Distal pancreatectomy for pancreatic neoplasia: is splenectomy really necessary? A bicentric retrospective analysis of surgical specimens.

J. Van Laethem, M. Komuta, N. D’haene, 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?

J. Van Laethem, M. Bali, J. Closset, 2021, Annals of Surgical Oncology.

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

C. Sempoux, E. Van Cutsem, C. Verslype, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

J. Vandesompele, P. Laurent-Puig, E. Van Cutsem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

J. Nippgen, P. Rougier, M. Peeters, 2009, BMC Cancer.

COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN COMPARED WITH CURRENT CARE IN METASTATIC COLORECTAL CANCER AFTER FAILURE ON IRINOTECAN – A BELGIAN ANALYSIS

E. Van Cutsem, Y. Humblet, L. Annemans, 2007, Acta clinica Belgica.

Quality of care indicators in rectal cancer.

K. Haustermans, E. Van Cutsem, P. Scalliet, 2011, Acta gastro-enterologica Belgica.

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

E. Van Cutsem, B. Nordlinger, M. Ducreux, 2005, European journal of cancer.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

E. Van Cutsem, L. Dirix, M. Borner, 2005, British Journal of Cancer.

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.

E. Van Cutsem, J. Tabernero, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy in gastric and cardia cancer: should we irradiate?

J. Van Laethem, A. Demols, 2006, Current opinion in oncology.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

K. Haustermans, F. Lordick, M. Ducreux, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The role of surgery and transplantation in neuroendocrine tumours.

P. Pattyn, C. Verslype, M. Peeters, 2009, Acta gastro-enterologica Belgica.

Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study.

P. van Houtte, I. Nakadi, R. Miller, 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

The lack of selection criteria for surgery in patients with non-colorectal non-neuroendocrine liver metastases

V. Donckier, J. Van Laethem, V. Lucidi, 2020, World Journal of Surgical Oncology.

Dataset for the reporting of carcinoma of the exocrine pancreas: recommendations from the International Collaboration on Cancer Reporting (ICCR)

S. Kakar, A. Krasinskas, J. Kench, 2021, Histopathology.

Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.

J. Devière, G. Verset, J. Van Laethem, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

D. Aust, M. Büchler, P. Laurent-Puig, 2017, European Journal of Cancer.

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma

L. Moretti, J. Van Laethem, P. Loi, 2021, Therapeutic advances in medical oncology.

J. Van Laethem, J. Yernault, A. Michils, 1995, Cancer.

Sixteen-year follow-up of Barrett’s esophagus, endoscopically treated with argon plasma coagulation

J. Devière, D. Bléro, A. Calomme, 2014, United European gastroenterology journal.

Follow-up of Barrett's epithelium after ablation by endoscopic argon plasma coagulation.

J. Devière, J. Van Laethem, P. Eisendrath, 2001, Gastrointestinal endoscopy.

Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis.

J. Devière, M. Delhaye, E. Quertinmont, 2002, American journal of physiology. Gastrointestinal and liver physiology.

Circulating DNA in the neoadjuvant setting of early stage colon cancer

P. Flamen, F. Rothé, M. Peeters, 2022, Acta oncologica.

N-Acetylcysteine Decreases Severity of Acute Pancreatitis in Mice

J. Devière, E. Quertinmont, J. Van Laethem, 2000, Pancreas.

Biliary tract cancers: From pathogenesis to endoscopic treatment

J. Devière, J. Van Laethem, R. Maréchal, 2007 .

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Endoscopic therapy of Barrett’s: what more do we need to know?

J. Devière, J. Van Laethem, J. Laethem, 2004, Gut.

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

M. Buyse, L. Moretti, P. Flamen, 2021, Acta oncologica.

Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT).

P. Flamen, M. Paesmans, J. Van Laethem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

John R. Mackey, Isabelle Salmon, Marc Peeters, 2009, Clinical Cancer Research.

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma

J. Mackey, C. Cass, I. Salmon, 2010, Cancer.

HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment

J. Van Laethem, R. Maréchal, 2009, Expert review of anticancer therapy.

Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.

P. van Houtte, F. Gay, M. Peeters, 2005, International journal of radiation oncology, biology, physics.

Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.

P. Houtte, F. Gay, M. Polus, 2003, International journal of radiation oncology, biology, physics.

Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases.

D. Larsimont, P. Vermeulen, L. Dirix, 2022, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC.

E. Van Cutsem, C. Verslype, M. Peeters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Argon plasma coagulation in Barrett's esophagus.

D. Franchimont, J. Devière, J. Van Laethem, 2003, Gastrointestinal endoscopy clinics of North America.

Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice.

J. Devière, P. Robberecht, J. Van Laethem, 1996, Gastroenterology.

Interleukin 10 prevents necrosis in murine experimental acute pancreatitis.

J. Devière, M. Goldman, A. Marchant, 1995, Gastroenterology.

Predictive factors for survival in patients with inoperable Klatskin tumors.

J. Devière, J. Van Laethem, O. le Moine, 2006, Hepato-gastroenterology.

Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitization.

J. Van Laethem, P. Eisendrath, Jean-Luc Van Laethem, 2002, Gastrointestinal endoscopy.

Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Manuel Hidalgo, Volker Heinemann, R. Labianca, 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Isabelle Salmon, Kathryn Graham, John R Mackey, 2012, Gastroenterology.

Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Management

J. Devière, F. Puleo, J. Bachet, 2016, Pancreas.

Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer.

E. Van Cutsem, J. Canon, F. Baert, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of Clinical Oncology.

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.

R. Abrams, J. Berlin, T. Conroy, 2022, JAMA oncology.

Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?

J. Van Laethem, N. D’haene, M. Pezzullo, 2020, European journal of cancer.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

A. Duval, J. Vaillant, J. Iovanna, 2017, Gastroenterology.

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: A phase II study of the Belgian Group of Digestive Oncology.

E. Van Cutsem, C. Verslype, P. Vergauwe, 2011, Journal of Clinical Oncology.

Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study.

F. Gay, M. Peeters, M. Polus, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study

M. Ducreux, M. Besselink, M. Lesurtel, 2019, BMC Cancer.

Ki‐Ras Oncogene Mutations in Chronic Pancreatitis: Which Discriminating Ability for Malignant Potential?

J. Van Laethem, 1999, Annals of the New York Academy of Sciences.

Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer

I. Borbath, K. Geboes, J. Van Laethem, 2022, ESMO open.

Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells: What Do We Know So Far?

M. Delhaye, F. Puleo, P. Demetter, 2021, Frontiers in Oncology.

Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation

L. Moretti, J. Van Laethem, M. Bali, 2022, Cancers.

Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours.

J. Devière, P. Robberecht, J. Van Laethem, 1995, Gut.

Exploring Limits for Data Registration in the Context of PROCARE, a Quality Improvement Project on Rectal Cancer

K. Haustermans, P. Demetter, J. Van Laethem, 2012, Acta chirurgica Belgica.

Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation.

J. Parma, J. Devière, V. De Maertelaer, 2004, Endoscopy.

Peritoneal patch in vascular reconstruction during pancreaticoduodenectomy for pancreatic cancer: a single Centre experience

J. Van Laethem, N. D’haene, M. Bali, 2021, Acta chirurgica Belgica.

New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients

N. Boon, V. Donckier, J. Van Laethem, 2003, Journal of surgical oncology.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

E. Van Cutsem, Y. Humblet, S. Tejpar, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Localization of transforming growth factor β1 and its latent binding protein in human chronic pancreatitis

K. Miyazono, J. Devière, H. Ohtani, 1995 .

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

C. Decaestecker, I. Salmon, J. Devière, 2009, British Journal of Cancer.

CD4(+ )T cells play an important role in acute experimental pancreatitis in mice.

O. Moine, J. Devière, E. Quertinmont, 2000, Gastroenterology.

Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice

J. Devière, P. Robberecht, J. Van Laethem, 1998, Gut.

Overexpression of pterin-4a-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 in human colon cancer.

C. Heizmann, B. Thöny, P. Robberecht, 1999, The American journal of pathology.

Discovery and 3D imaging of a novel ΔNp63-expressing basal cell type in human pancreatic ducts with implications in disease

F. Real, I. Rooman, L. Bouwens, 2020, bioRxiv.

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

I. Salmon, J. Devière, S. Tejpar, 2010, BMC Cancer.

Aquaporins Involvement in Pancreas Physiology and in Pancreatic Diseases

C. Delporte, J. Van Laethem, J. Perret, 2019, International journal of molecular sciences.

Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features

M. Radman, V. Paradis, J. Emile, 2021, Cancers.

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges

K. Coulonval, E. Raspé, P. Roger, 2023, Cancers.

Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?

L. Moretti, J. Van Laethem, A. Hendlisz, 2020, Therapeutic advances in medical oncology.

Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer.

J. Van Laethem, 2019, European journal of cancer.

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

T. Conroy, K. Haustermans, M. Ducreux, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

I. Salmon, J. Devière, J. Vaillant, 2014, Clinical Cancer Research.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Huyuan Yang, P. Enzinger, J. Bendell, 2017, Investigational New Drugs.

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

J. Bendell, M. Alsina, W. Messersmith, 2017, Investigational New Drugs.

Treatment of Pancreatic Cancer: What Can We Really Predict Today?

J. Bachet, J. Van Laethem, R. Maréchal, 2011, Cancers.

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

A. Stenzinger, E. Van Cutsem, T. Seufferlein, 2021, Cancers.

PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker

R. Tomasini, J. Iovanna, E. Folch-Puy, 2017, Cellular and Molecular Life Sciences.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.

Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind

F. Puleo, P. Demetter, J. Van Laethem, 2021, Cancers.

Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications.

A. Biankin, I. Rooman, F. Puleo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

E. Van Cutsem, P. Flamen, C. Verslype, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

L. Collette, R. Salazar, P. Laurent-Puig, 2014, The Lancet. Oncology.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

D. Franchimont, P. Laurent-Puig, J. Devière, 2018, Gastroenterology.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2017, JAMA oncology.

Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.

E. Van Cutsem, T. Gruenberger, M. Ducreux, 2017, European journal of cancer.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.

P. Scalliet, T. Boterberg, I. Borbath, 2009, Annals of Oncology.

Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus

I. Salmon, J. Devière, J. Van Laethem, 2000, Gut.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

D. V. Von Hoff, H. Oettle, A. Zimmermann, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

E. Van Cutsem, Y. Humblet, M. Debiec‐Rychter, 2008, Clinical Cancer Research.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

E. Van Cutsem, Y. Humblet, S. Patterson, 2013, Clinical Cancer Research.

An update on treatment options for pancreatic adenocarcinoma

T. Conroy, M. Ducreux, I. Borbath, 2019, Therapeutic advances in medical oncology.

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases

B. Neyns, P. van Dam, G. Verset, 2019, ESMO Open.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy

P. Laurent-Puig, J. Tabernero, C. Lepage, 2018, Clinical Cancer Research.

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer

M. Piccart, P. Flamen, R. Lhommel, 2015, PloS one.

The Relationship between a New Biomarker of Vagal Neuroimmunomodulation and Survival in Two Fatal Cancers

Y. Gidron, J. De Grève, J. Van Laethem, 2018, Journal of immunology research.

Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation.

Y. Gidron, J. Van Laethem, R. Maréchal, 2016, Cancer epidemiology.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

W. Scheithauer, E. Van Cutsem, M. Moore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Follow-Up and Factors Predictive of Recurrence in Barrett's Esophagus Treated by Argon Plasma Coagulation and Acid Suppression

J. Devière, M. Kahaleh, J. Van Laethem, 2002, Endoscopy.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

A. Carrato, L. Lipton, C. Fuchs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Emerging drugs for the treatment of pancreatic cancer

J. Van Laethem, R. Maréchal, 2007, Expert opinion on emerging drugs.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016, JAMA oncology.

Systemic treatment of pancreatic cancer revisited.

T. Conroy, P. Laurent-Puig, M. Ducreux, 2019, Seminars in oncology.

Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.

G. Verset, J. Van Laethem, R. Sakr, 2021, European journal of cancer.

Predictive value of neutrophils count for local tumor control after chemoradiotherapy in patients with locally advanced pancreatic carcinoma.

P. van Houtte, D. Goldstein, A. Schernberg, 2021, International journal of radiation oncology, biology, physics.

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.

A. Reyniès, J. Iovanna, N. Dusetti, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

R. Labianca, H. Friess, J. Berlin, 2018, The Lancet. Oncology.

Current standards and new innovative approaches for treatment of pancreatic cancer.

T. Conroy, M. Ducreux, A. Ayav, 2016, European journal of cancer.

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

E. Van Cutsem, M. Moore, T. Ciuleanu, 2014, British Journal of Cancer.

Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.

I. Colle, H. Van Vlierberghe, N. Boon, 2004, Transplant immunology.

Expression of transforming growth factor beta receptors in normal human colon and sporadic adenocarcinomas.

P. Robberecht, J. Van Laethem, M. Svoboda, 1998, Gastroenterology.

Interleukin‐10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice

Wei Wu, J. Devière, M. Goldman, 1998, Hepatology.

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

A. Gasbarrini, C. Porta, H. Van Vlierberghe, 2016, Oncotarget.

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

R. Labianca, D. Kerr, P. Johnston, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinico‐metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases

D. Larsimont, S. Goldman, P. Vermeulen, 2021, Journal of surgical oncology.

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

C. Verslype, I. Borbath, S. Francque, 2007, British Journal of Cancer.

Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.

D. Franchimont, P. van Houtte, M. Polus, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

L. Collette, V. Budach, K. Haustermans, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases.

J. Parma, J. Devière, V. Bourgeois, 1998, Gastrointestinal endoscopy.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas†

R. Korn, J. Tabernero, D. V. Von Hoff, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

F. Gay, M. Peeters, M. Polus, 2006, British Journal of Cancer.

Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer

F. Gay, J. Van Laethem, R. Maréchal, 2008, Oncology.

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

E. Van Cutsem, J. Tabernero, G. Tortora, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New challenges in perioperative management of pancreatic cancer.

J. Devière, F. Puleo, J. Bachet, 2015, World journal of gastroenterology.

Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.

V. Donckier, J. Van Laethem, V. Lucidi, 2016, World journal of gastroenterology.

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

M. Piccart, M. Maetens, P. Flamen, 2015, BMC Cancer.

Different Expression of Transforming Growth Factor β1 in Pancreatic Ductal Adenocarcinoma and Cystic Neoplasms

J. Devière, P. Robberecht, J. Van Laethem, 1997, Pancreas.

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

A. Gasbarrini, C. Porta, C. Gridelli, 2013, The Lancet. Oncology.

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials

P. Flamen, M. Paesmans, L. Ameye, 2019, BMC Cancer.

What treatment in 2017 for inoperable pancreatic cancers?

M. Reni, F. Lordick, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.

D. Larsimont, F. Cardoso, M. Paesmans, 2005, Seminars in oncology.

Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA.

P. Rougier, M. Peeters, J. Raoul, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Critical Reviews in Oncology/Hematology

M. Ceppi, E. de Azambuja, R. Caparica, 2016 .

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial - REACHIN.

M. Paesmans, M. Peeters, I. Borbath, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma.

J. Emile, P. Hammel, J. Cros, 2021, European journal of cancer.

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

D. Aust, T. Conroy, J. Neoptolemos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report

K. Sheahan, N. Swan, J. Van Laethem, 2021, Diagnostic Pathology.

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

L. Collette, G. Calais, M. Bolla, 2014, The Lancet. Oncology.

Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study.

D. Goldstein, F. Bonnetain, B. Glimelius, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?

L. Moretti, J. Van Laethem, T. Arsenijevic, 2023, Cancers.

Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST.

T. Metens, J. Absil, C. Matos, 2018, European journal of radiology.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

Tolerance and Efficacy of Gemcitabine and Gemcitabine-Based Regimens in Elderly Patients With Advanced Pancreatic Cancer

F. Gay, V. De Maertelaer, J. Van Laethem, 2008, Pancreas.

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2020, JCO precision oncology.

Local Ablative Treatments for Liver Metastases: The Current Situation

S. Goldman, V. Donckier, J. Van Laethem, 2003, Acta chirurgica Belgica.

A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer.

D. V. Von Hoff, H. Oettle, M. Arning, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.

I. Salmon, J. Vaillant, A. Sauvanet, 2013, European journal of cancer.

Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.

I. Salmon, P. Rougier, J. Vaillant, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.

E. Van Cutsem, P. Pattyn, C. Verslype, 2009, Acta gastro-enterologica Belgica.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2020, European Journal of Cancer.

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma.

P. van Houtte, D. Goldstein, N. Spry, 2021, International journal of radiation oncology, biology, physics.

EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and oligometastatic disease: an observational prospective multicenter study

J. Devière, I. Borbath, R. Garcés-Durán, 2022, Endoscopy international open.

Treatment sequence of synchronously (liver) metastasized colon cancer.

R. Labianca, E. Van Cutsem, T. Gruenberger, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group.

D. Wagener, B. Baron, J. Van Laethem, 2004, European journal of cancer.

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial

M. Ignatiadis, M. Maetens, M. Paesmans, 2019, BMC Cancer.

Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: Updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203).

V. Budach, K. Haustermans, E. Van Cutsem, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Esophageal cancer: Outcome and potential benefit of esophagectomy in elderly patients

J. Van Laethem, R. Maréchal, I. El Nakadi, 2022, Thoracic cancer.

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

E. Van Cutsem, B. Nordlinger, M. Ducreux, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials

P. Flamen, M. Paesmans, L. Ameye, 2019, BMC Cancer.

[F‐18] Fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases

S. Goldman, D. Wikler, V. Donckier, 2003, Journal of surgical oncology.

Carcinoid heart disease--a hidden complication of neuroendocrine tumours.

E. Van Cutsem, P. Pattyn, C. Verslype, 2009, Acta gastro-enterologica Belgica.

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas

F. Speleman, P. Pauwels, F. Baert, 2010, BMC Cancer.

Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

P. Laurent-Puig, E. Van Cutsem, J. Tabernero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

Salvage esophagectomy after failure of definitive radiochemotherapy for esophageal cancer

M. Paesmans, J. Van Laethem, R. Maréchal, 2016, Journal of surgical oncology.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience

I. Salmon, B. Meléndez, P. Demetter, 2018, Oncotarget.

Clinical impact of 99mTc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a real-life single-center experience in unresectable HCC patients

N. Trotta, G. Verset, J. Van Laethem, 2023, European Journal of Hybrid Imaging.

Neoadjuvant chemotherapy associated with isotoxic high‐dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduodenectomy for nonmetastatic pancreatic cancer

J. Van Laethem, P. Loi, J. Closset, 2023, Journal of surgical oncology.

The role of PET scan in the preoperative management of oesophageal cancer.

S. Goldman, F. Gay, J. Van Laethem, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response

O. Peulen, A. Bellahcène, J. Van Laethem, 2023, Cells.

Raltitrexed plus Gemcitabine (TOMGEM) in Advanced Pancreatic Cancer

E. Van Cutsem, C. Verslype, M. Polus, 2005, Oncology.

EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score

L. Moretti, J. Van Laethem, P. Eisendrath, 2021, Endoscopy International Open.

ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION VERSUS SURGICAL RESECTION FOR TREATMENT OF PANCREATIC INSULINOMA.

H. Jacob, P. Vilmann, M. Falconi, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

502PDMOSAIC STUDY: ACTUALIZATION OF OVERALL SURVIVAL (OS) WITH 10 YEARS FOLLOW UP AND EVALUATION OF BRAF. BY GERCOR AND MOSAIC INVESTIGATORS.

W. Scheithauer, T. Hickish, A. Duval, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

G. Vanhoutte, M. Peeters, P. Vergauwe, 2023, Therapeutic Advances in Medical Oncology.

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy

C. Decaestecker, I. Salmon, J. Van Laethem, 2023, Cancers.

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

P. Flamen, M. Peeters, P. Vergauwe, 2021, Clinical colorectal cancer.

A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.

J. Van Laethem, F. Gay, A. Hendlisz, 2001, European journal of cancer.